Citadel Advisors
LYRA

Citadel Advisors’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Citadel Advisors’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-678
Closed -$4.28K – 14002
2025
Q1 		$4.28K Buy
+678
New +$6.34K ﹤0.01% 13903
2024
Q4 		– Sell
-8
Closed -$103 – 15030
2024
Q3 		$103 Sell
8
-4
-33% -$59 ﹤0.01% 14089
2024
Q2 		$166 Sell
12
-14
-54% -$1.58K ﹤0.01% 14080
2024
Q1 		$8.09K Sell
26
-20
-43% -$5.33K ﹤0.01% 13575
2023
Q4 		$12.1K Buy
46
+16
+53% +$2.9K ﹤0.01% 13012
2023
Q3 		$5.87K Buy
30
+22
+275% +$3.94K ﹤0.01% 13361
2023
Q2 		$1.64K Sell
8
-2
-20% -$278 ﹤0.01% 13893
2023
Q1 		$1.03K Sell
10
-2
-17% -$248 ﹤0.01% 14378
2022
Q4 		$1.88K Buy
+12
New +$2.38K ﹤0.01% 14405

Other funds holding LYRA

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Citadel Advisors's LYRA Position: Q4 2025 in Review

Citadel Advisors sold out of LYRA THERAPEUTICS INC (LYRA) in Q4 2025, closing a stake of 19,484 shares — an estimated $128K sold.

Citadel Advisors first reported a position in LYRA in Q2 2020 and held it in 13 quarters. The position peaked at $27M in Q1 2024. 23 funds tracked by Wall St. Rank hold LYRA as of Q4 2025.

  • Citadel Advisors reported no remaining LYRA THERAPEUTICS INC position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 19,484 LYRA THERAPEUTICS INC shares in Q4 2025, an estimated $128K.
  • Citadel Advisors first reported a position in LYRA THERAPEUTICS INC in Q2 2020 and held it in 13 quarters.
  • Citadel Advisors's LYRA THERAPEUTICS INC position peaked at $27M in Q1 2024.
  • 23 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.